Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
November 2014—GenoLogics has been selected by Illumina as the laboratory information management system provider to support customers of the HiSeq X Ten sequencing system. Under the agreement, the companies will provide support for HiSeq X Ten whole-genome workflows and analysis pipelines, including those to be used inside of Illumina.
October 2014—Neoteryx announced the launch of the Mitra (RUO) Microsampling Device for the collection, transport, storage, and analysis of biological fluids. In seconds, the research-use-only Mitra microsampler consistently collects 10 µL of fluid while eliminating the volumetric blood hematocrit bias typically associated with the dried blood spotting technique.
October 2014—AstraZeneca announced it has entered into a collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small cell lung cancer.
October 2014—Enzo Life Sciences now offers the Amp’d GLP-1 ELISA Kit, a rapid ELISA for the detection of the active form of glucagon-like peptide 1. The kit can be used to quantify the active form of human GLP-1 in serum and plasma samples.
October 2014—Viewics released its Utilization Management solution specifically designed for laboratories. The Viewics solution enables laboratories and pathology groups to leverage massive amounts of data into customized dashboards, analyses, and insights that drive successful utilization management initiatives.
October 2014—The Cells-to-CT 1-Step Power SYBR Green Kit from Life Technologies makes it possible to perform expression analysis directly from cultured cells without RNA purification. This new addition includes cell lysis reagents with gDNA removal and the Power SYBR Green 1-Step RT-PCR master mix.
October 2014—The Viaflo Assist is a multichannel pipette from Integra that works with Viaflo II electronic pipettes to prevent users from repetitive strain injuries and to significantly increase the reproducibility of prolonged pipetting protocols such as serial dilutions, plate fillings, and reagent addition.
October 2014—Illumina announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation-sequencing-based oncology test system.
October 2014—The bioT3 Metastatic Cancer Solution from BioTheranostics now includes a single assay that covers genetic mutations and protein expression.
